Drug intelligence / Profile preview

insulin human + basal insulin

Development stage
Unknown
Lead developer
Novo Nordisk
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

This is a **combination therapy** comprising **human insulin** and a **basal insulin**. Human insulin is a recombinant form of the naturally occurring hormone insulin, regulating glucose metabolism by facilitating cellular glucose uptake and inhibiting hepatic glucose output. "Basal insulin" refers to **long-acting formulations** (such as insulin glargine, insulin detemir, or NPH insulin), which provide steady insulin levels to control blood sugar between meals and overnight. The mechanism of action involves **agonism of the insulin receptor**, leading to enhanced glucose uptake and reduced hepatic glucose production. The primary indication is **diabetes mellitus** (Type 1 and Type 2), particularly when intensified insulin management is required. This combination allows both prandial and basal glycemic control, either as separate injections or in some formulations as a fixed ratio (sometimes called "basal plus" therapy). Combination therapy may reduce the risk of hypoglycemia and weight gain versus more complex insulin regimens[2][3][4].

02

Targets

IGF-1R (Insulin-like growth factor 1 receptor)INSR (Insulin receptor)

Beyond the preview

Go deeper on insulin human + basal insulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin human + basal insulin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call